News - Anti-virals, Eviplera


Current filters:


Popular Filters

US FDA backs new indication for Gilead's Complera

US FDA backs new indication for Gilead's Complera


US biotech firm Gilead Sciences’ share closed up 1.6% at $71.40 on Friday, following the news of an…

Anti-viralsBiotechnologyCompleraEvipleraGilead SciencesNorth AmericaRegulation

J&J'S rilpivirine also proven for combination HIV product, says IQWiG


Since the start of 2012, a new drug - rilpivirine from US health care giant Johnson & Johnson (NYSE:…

Anti-viralsEuropeEvipleraJohnson & JohnsonPharmaceuticalPricingRegulationrilpivirine

Gilead and Johnson & Johnson get EU backing for HIV drugs Eviplera and Edurant, respectively


In the first of two pieces of good news for HIV/AIDS drug developers, US biotech firm Gilead Sciences…

Anti-viralsEdurantEuropeEvipleraGilead SciencesJanssen-CilagJohnson & JohnsonPharmaceuticalRegulationTibotec

More news from EMA/CHMP September meeting


Following its meetings last week, the European Medicines Agency’s Committee for Medicinal Products…

Anti-viralsAntibiotics and Infectious diseasesAstellas PharmaCelgeneDificidDificlirEuropeEvipleraGilead SciencesOncologyPharmaceuticalRegulationRevlimidUCBVimpat

Back to top